Compare YSXT & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | ASRT |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 75.1M |
| IPO Year | 2024 | 1997 |
| Metric | YSXT | ASRT |
|---|---|---|
| Price | $1.23 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 1.1M | 313.9K |
| Earning Date | 07-31-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | $71,452,736.00 | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.68 | ★ N/A |
| Revenue Growth | ★ 22.04 | 9.22 |
| 52 Week Low | $1.13 | $0.51 |
| 52 Week High | $9.96 | $1.01 |
| Indicator | YSXT | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 27.71 | 41.47 |
| Support Level | $1.13 | $0.75 |
| Resistance Level | $1.80 | $0.80 |
| Average True Range (ATR) | 0.33 | 0.04 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 7.58 | 23.22 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.